244 related articles for article (PubMed ID: 36632223)
21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
22. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
23. Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer.
Inaba K; Tsuchida K; Kashihara T; Umezawa R; Takahashi K; Okuma K; Murakami N; Ito Y; Igaki H; Sumi M; Nakayama Y; Shinoda Y; Hara T; Matsui Y; Komiyama M; Fujimoto H; Itami J
J Radiat Res; 2021 May; 62(3):511-516. PubMed ID: 33822986
[TBL] [Abstract][Full Text] [Related]
24. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
[TBL] [Abstract][Full Text] [Related]
25. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
[TBL] [Abstract][Full Text] [Related]
26. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
[TBL] [Abstract][Full Text] [Related]
27. Impact of Radiotherapy on Prognosis in Patients Diagnosed with Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Liu S; Wang XY; Huang TB; Ma XX; Xia ZZ; Tang LB; Zhao TS; Zhou GC
Urol Int; 2021; 105(5-6):370-379. PubMed ID: 33302278
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
29. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
30. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
Wu X; Scott H; Carlsson SV; Sjoberg DD; Cerundolo L; Lilja H; Prevo R; Rieunier G; Macaulay V; Higgins GS; Verrill CL; Lamb AD; Cunliffe VT; Bountra C; Hamdy FC; Bryant RJ
Prostate; 2019 Jul; 79(10):1079-1089. PubMed ID: 31104332
[TBL] [Abstract][Full Text] [Related]
31. Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.
Qu M; Zhu F; Chen H; Lian B; Jia Z; Shi Z; Li J; Wang Y; Sun Y; Gao X
J Endourol; 2019 Jul; 33(7):570-575. PubMed ID: 31025578
[No Abstract] [Full Text] [Related]
32. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
Siu MK; Abou-Kheir W; Yin JJ; Chang YS; Barrett B; Suau F; Casey O; Chen WY; Fang L; Hynes P; Hsieh YY; Liu YN; Huang J; Kelly K
Oncotarget; 2014 Jun; 5(11):3770-84. PubMed ID: 25004126
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer.
Sun Y; Chen G; He J; Huang ZG; Li SH; Yang YP; Zhong LY; Ji SF; Huang Y; Chen XH; He ML; Wu H
Bioengineered; 2021 Dec; 12(1):325-340. PubMed ID: 33356818
[TBL] [Abstract][Full Text] [Related]
34. GAS1RR, an immune-related enhancer RNA, is related to biochemical recurrence-free survival in prostate cancer.
Xiong Z; Ge Y; Xiao J; Wang Y; Li L; Ma S; Lan L; Liu B; Qin B; Luan Y; Yang C; Ye Z; Wang Z
Exp Biol Med (Maywood); 2023 Jan; 248(1):1-13. PubMed ID: 36408742
[TBL] [Abstract][Full Text] [Related]
35. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
36. The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort.
Keam SP; Caramia F; Gamell C; Paul PJ; Arnau GM; Neeson PJ; Williams SG; Haupt Y
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):188-198. PubMed ID: 29102647
[TBL] [Abstract][Full Text] [Related]
37. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
[TBL] [Abstract][Full Text] [Related]
38. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
Helo P; Cronin AM; Danila DC; Wenske S; Gonzalez-Espinoza R; Anand A; Koscuiszka M; Väänänen RM; Pettersson K; Chun FK; Steuber T; Huland H; Guillonneau BD; Eastham JA; Scardino PT; Fleisher M; Scher HI; Lilja H
Clin Chem; 2009 Apr; 55(4):765-73. PubMed ID: 19233911
[TBL] [Abstract][Full Text] [Related]
39. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.
Fu Z; Dozmorov IM; Keller ET
Prostate; 2002 Apr; 51(1):10-20. PubMed ID: 11920953
[TBL] [Abstract][Full Text] [Related]
40. miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.
Ray J; Haughey C; Hoey C; Jeon J; Murphy R; Dura-Perez L; McCabe N; Downes M; Jain S; Boutros PC; Mills IG; Liu SK
Cancer Lett; 2020 Mar; 473():107-117. PubMed ID: 31874245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
